Search Results - Richard A. Larson

Refine Results
  1. 1
    Therapy-related myeloid neoplasms

    Therapy-related myeloid neoplasms by Richard A. Larson

    Published 2009-04-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    PROGNOSIS AND THERAPY WHEN ACUTE PROMYELOCYTIC LEUKEMIA AND OTHER “GOOD RISK” ACUTE MYELOID LEUKEMIAS OCCUR AS A THERAPY-RELATED MYELOID NEOPLASM

    PROGNOSIS AND THERAPY WHEN ACUTE PROMYELOCYTIC LEUKEMIA AND OTHER “GOOD RISK” ACUTE MYELOID LEUKEMIAS OCCUR AS A THERAPY-RELATED MYELOID NEOPLASM by Richard A. Larson, Michelle Le Beau

    Published 2011-07-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis

    Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis by Richard M. Stone, Paul W. Manley, Richard A. Larson, Renaud Capdeville

    Published 2018-02-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Allogeneic Hematopoietic Cell Transplantation for Therapy-Related Myeloid Leukemia following Orthotopic Cardiac Transplantation

    Allogeneic Hematopoietic Cell Transplantation for Therapy-Related Myeloid Leukemia following Orthotopic Cardiac Transplantation by Richard J. Lin, Richard A. Larson, Koen van Besien, Elizabeth S. Rich

    Published 2013-01-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    High rates of durable response are achieved with imatinib after treatment with interferon α plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial

    High rates of durable response are achieved with imatinib after treatment with interferon α plus cytarabine: results from the International Randomized Study of Interferon and STI57... by François Guilhot, Brian Druker, Richard A. Larson, Insa Gathmann, Charlene So, Roger Waltzman, Stephen G. O’Brien

    Published 2009-12-01
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia

    Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia by Anthony S. Stein, Richard A. Larson, Andre C. Schuh, William Stevenson, Ewa Lech-Maranda, Qui Tran, Zachary Zimmerman, William Kormany, Max S. Topp

    Published 2018-07-01
    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients

    Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients by Lori S. Muffly, Masha Kocherginsky, Wendy Stock, Quynh Chu, Michael R. Bishop, Lucy A. Godley, Justin Kline, Hongtao Liu, Olatoyosi M. Odenike, Richard A. Larson, Koen van Besien, Andrew S. Artz

    Published 2014-08-01
    Get full text
    Article
    Save to List
    Saved in:
  8. 8
    Intensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classification

    Intensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European... by Meir Wetzler, Krzysztof Mrózek, Jessica Kohlschmidt, Hervé Dombret, Hartmut Döhner, Sylvain Pilorge, Utz Krug, Andrew J. Carroll, Richard A. Larson, Guido Marcucci, Wolfgang Hiddemann, Thomas Büchner, Clara D. Bloomfield

    Published 2014-02-01
    Get full text
    Article
    Save to List
    Saved in:
  9. 9
    WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia

    WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia by Hongtao Liu, Yuanyuan Zha, Noura Choudhury, Gregory Malnassy, Noreen Fulton, Margaret Green, Jae-Hyun Park, Yusuke Nakamura, Richard A. Larson, Andres M. Salazar, Olatoyosi Odenike, Thomas F. Gajewski, Wendy Stock

    Published 2018-01-01
    Get full text
    Article
    Save to List
    Saved in:
  10. 10
    Outcomes following second allogeneic stem cell transplant for disease relapse after T cell depleted transplant correlate with remission status and remission duration after the first transplant

    Outcomes following second allogeneic stem cell transplant for disease relapse after T cell depleted transplant correlate with remission status and remission duration after the firs... by Yun Fan, Andrew S. Artz, Koen van Besien, Wendy Stock, Richard A. Larson, Olatoyosi Odenike, Lucy A. Godley, Justin Kline, John M. Cunningham, James L. LaBelle, Michael R. Bishop, Hongtao Liu

    Published 2019-01-01
    Get full text
    Article
    Save to List
    Saved in:
  11. 11
    Efficacy and tolerability of a modified pediatric‐inspired intensive regimen for acute lymphoblastic leukemia in older adults

    Efficacy and tolerability of a modified pediatric‐inspired intensive regimen for acute lymphoblastic leukemia in older adults by Anand Ashwin Patel, Joseph Heng, Emily Dworkin, Sarah Monick, Benjamin A. Derman, Adam S. DuVall, Sandeep Gurbuxani, Satyajit Kosuri, Hongtao Liu, Michael Thirman, Lucy A. Godley, Olatoyosi Odenike, Richard A. Larson, Wendy Stock

    Published 2021-08-01
    Get full text
    Article
    Save to List
    Saved in:
  12. 12
    GENETIC PATHWAYS LEADING TO THERAPY-RELATED MYELOID NEOPLASMS

    GENETIC PATHWAYS LEADING TO THERAPY-RELATED MYELOID NEOPLASMS by Angela Stoddart, Megan E. McNerney, Elizabeth Bartom, Rachel Bergerson, David J. Young, Zhijian Qian, Jianghong Wang, Anthony A. Fernald, Elizabeth M. Davis, Richard A. Larson, Kevin P. White, Michelle M. Le Beau

    Published 2011-05-01
    Get full text
    Article
    Save to List
    Saved in:
  13. 13
    GENETIC PATHWAYS LEADING TO THERAPY-RELATED MYELOID NEOPLASMS

    GENETIC PATHWAYS LEADING TO THERAPY-RELATED MYELOID NEOPLASMS by Rachel Bergerson, Elizabeth Bartom, Megan E. McNerney, Angela Stoddart, David J. Young, Zhijian Qian, Jianghong Wang, Anthony A. Fernald, Elizabeth M. Davis, Richard A. Larson, Kevin P. White, Michelle M. Le Beau

    Published 2011-01-01
    Get full text
    Article
    Save to List
    Saved in:
  14. 14
    Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance)

    Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (... by Meir Wetzler, Dorothy Watson, Wendy Stock, Gregory Koval, Flora A. Mulkey, Eva E. Hoke, John M. McCarty, William G. Blum, Bayard L. Powell, Guido Marcucci, Clara D. Bloomfield, Charles A. Linker, Richard A. Larson

    Published 2014-01-01
    Get full text
    Article
    Save to List
    Saved in:
  15. 15
    RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia

    RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia by Jason X. Cheng, Li Chen, Yuan Li, Adam Cloe, Ming Yue, Jiangbo Wei, Kenneth A. Watanabe, Jamile M. Shammo, John Anastasi, Qingxi J. Shen, Richard A. Larson, Chuan He, Michelle M. Le Beau, James W. Vardiman

    Published 2018-03-01
    Get full text
    Article
    Save to List
    Saved in:
  16. 16
    Author Correction: RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia

    Author Correction: RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia by Jason X. Cheng, Li Chen, Yuan Li, Adam Cloe, Ming Yue, Jiangbo Wei, Kenneth A. Watanabe, Jamile M. Shammo, John Anastasi, Qingxi J. Shen, Richard A. Larson, Chuan He, Michelle M. Le Beau, James W. Vardiman

    Published 2018-06-01
    Get full text
    Article
    Save to List
    Saved in:
  17. 17
    Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily

    Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imati... by Timothy P. Hughes, Andreas Hochhaus, Hagop M. Kantarjian, Francisco Cervantes, François Guilhot, Dietger Niederwieser, Philipp D. le Coutre, Gianantonio Rosti, Gert Ossenkoppele, Clarisse Lobo, Hirohiko Shibayama, Xiaolin Fan, Hans D. Menssen, Charisse Kemp, Richard A. Larson, Giuseppe Saglio

    Published 2014-07-01
    Get full text
    Article
    Save to List
    Saved in:
  18. 18
    A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia

    A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia by Amy Y. Wang, Howard Weiner, Margaret Green, Hua Chang, Noreen Fulton, Richard A. Larson, Olatoyosi Odenike, Andrew S. Artz, Michael R. Bishop, Lucy A. Godley, Michael J. Thirman, Satyajit Kosuri, Jane E. Churpek, Emily Curran, Kristen Pettit, Wendy Stock, Hongtao Liu

    Published 2018-01-01
    Get full text
    Article
    Save to List
    Saved in:
  19. 19
    Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia

    Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia by Kathryn E. Flynn, Ehab Atallah, Li Lin, Neil P. Shah, Richard T. Silver, Richard A. Larson, Javier Panilla-Ibarz, James E. Thompson, Vivian G. Oehler, Jerald P. Radich, Vamsi Kota, Michael J. Mauro, Charles A. Schiffer, Jorge Cortes, Kevin P. Weinfurt

    Published 2022-05-01
    Get full text
    Article
    Save to List
    Saved in:
  20. 20
    Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantation

    Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantation by Gregory W. Roloff, Satyajit Kosuri, Mariam T. Nawas, Adam S. DuVall, Anand A. Patel, Peter A. Riedell, Olatoyosi Odenike, Wendy Stock, Richard A. Larson, Michael R. Bishop, Emma Nunley, Lucy A. Godley, Feighanne Hathaway, Daniela del Gaudio, Soma Das, Lorraine E. Canham, Michael W. Drazer

    Published 2024-04-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: